{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T19:11:13Z","timestamp":1782587473931,"version":"3.54.5"},"reference-count":25,"publisher":"PeerJ","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National 13th Five-Year Science and Technology Major Project for control and prevention of AIDS, hepatitis and other major infectious disease","award":["2017ZX10302201-001"],"award-info":[{"award-number":["2017ZX10302201-001"]}]},{"name":"Hangzhou Science and Technology Development Special Project of Biopharmaceutical and Health Industry","award":["2023WJC192"],"award-info":[{"award-number":["2023WJC192"]}]},{"name":"Hangzhou Medical Science and Technology Project","award":["A20241871"],"award-info":[{"award-number":["A20241871"]}]},{"name":"Hangzhou Municipal Medical and Health Research Project","award":["ZD20230090"],"award-info":[{"award-number":["ZD20230090"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The correlation between hepatitis B virus (HBV) RNA, HBV DNA and hepatitis B surface antigen (HBsAg) during antiviral treatment and the clinical value of HBV RNA for virological response and drug discontinuance, are still unknown. This study was to investigate the clinical significance and predicting ability of HBV RNA for hepatitis B e antigen (HBeAg) seroconversion (SR) in chronic hepatitis B (CHB) patients receiving antiviral therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 138 patients with CHB who were newly diagnosed from January 2023 to December 2023 were enrolled in this study. Patients were divided into the SR group and the non-seroconversion (NSR) group according to HBeAg SR in baseline to the 60th week. The dynamic changes and correlations between HBV RNA, HBV DNA, HBsAg and HBeAg was analyzed between the two groups and the predictive values of them for HBeAg SR were calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The 60th week HBeAg SR rate was 23.9% (33\/138), patients treated with tenofovir alafenamide fumarate (TAF) had higher SR rate than others (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0&lt;\u00a00.001). After antiviral therapy, the serum HBV RNA levels of SR group decreased significantly than in the NSR group. Baseline HBV RNA levels were significantly correlated with HBV DNA, HBsAg and HBeAg in both groups, but weakened after antiviral therapy. Univariate and multivariate regression analysis showed that the serum HBV RNA levels at the 12th week was an independent predictor of HBeAg SR. The area under the receiver operating characteristic curve (AUROC) of the serum HBV RNA levels at the 12th week had a higher value (AUROC = 0.8039, 95% CI [0.691\u20130.917]). The cut off value of HBV RNA level with 5.68 lg copies\/ml at the 12th week had a sensitivity of 76.47% and a specificity of 72.55% for predicting HBeAg SR.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline HBV RNA levels in CHB patients exhibited a significantly positive correlation with HBV DNA and HBsAg levels, this correlation weakened after antiviral therapy. The serum HBV RNA level at the 12th week could serve as an early predictor for the HBeAg SR in patients with CHB. The CHB patients treated with antiviral drug TAF showed a higher HBeAg SR rate compared to ETV and TDF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.7717\/peerj.20275","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:53:56Z","timestamp":1761814436000},"page":"e20275","source":"Crossref","is-referenced-by-count":2,"title":["Clinical value of serum HBV RNA in patients with chronic hepatitis B during antiviral therapy"],"prefix":"10.7717","volume":"13","author":[{"given":"Xiaojing","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University,  Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing City, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University,  Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaofei","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University,  Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University,  Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University,  Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaguo","family":"Shao","sequence":"additional","affiliation":[{"name":"Institute of Hepatology and Epidemiology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou City, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shourong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Hangzhou Xixi Hospital Affiliated to Zhejiang Chinese Medical University,  Hangzhou, Zhejiang Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4443","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"issue":"12","key":"10.7717\/peerj.20275\/ref-1","first-page":"938","article-title":"The guidelines of prevention and treatment for chronic hepatitis B (2019 version)","volume":"27","author":"Chinese Society\u00a0of Infectious Diseases, Chinese Medical Association","year":"2019","journal-title":"Chinese Journal of Hepatology"},{"key":"10.7717\/peerj.20275\/ref-2","doi-asserted-by":"publisher","first-page":"116678","DOI":"10.1016\/j.biopha.2024.116678","article-title":"Pharmacogenetics of tenofovir drug transporters in the context of HBV: is there an impact?","volume":"175","author":"Cusato","year":"2024","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.7717\/peerj.20275\/ref-3","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.20275\/ref-4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.cgh.2019.07.046","article-title":"Association between negative results from tests for HBV DNA and RNA and durability of response after discontinuation of nucles(t)ide analogue therapy","volume":"18","author":"Fan","year":"2020","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"10.7717\/peerj.20275\/ref-5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection\u2014natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"New England Journal of Medicine"},{"key":"10.7717\/peerj.20275\/ref-6","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"7","author":"GBD 2019 Hepatitis B Collaborators","year":"2022","journal-title":"The Lancet Gastroenterology & Hepatology"},{"key":"10.7717\/peerj.20275\/ref-7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3851\/IMP2777","article-title":"On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy","volume":"20","author":"Huang","year":"2015","journal-title":"Antiviral Therapy"},{"key":"10.7717\/peerj.20275\/ref-8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jcv.2017.12.016","article-title":"Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-naive HBV-infected individuals","volume":"99\u2013100","author":"Huang","year":"2018","journal-title":"Journal of Clinical Virology"},{"key":"10.7717\/peerj.20275\/ref-9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12985-015-0447-5","article-title":"Mechanisms downstream of reverse transcription reduce serum levels of HBV DNA but not of HBsAg in chronic hepatitis B virus infection","volume":"12","author":"Larsson","year":"2015","journal-title":"Virology Journal"},{"key":"10.7717\/peerj.20275\/ref-10","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1111\/liv.14786","article-title":"Switching from entecavir to tenofovir alafenamide for chronic hepatitis B patients with low-level viraemia","volume":"41","author":"Li","year":"2021","journal-title":"Liver International"},{"key":"10.7717\/peerj.20275\/ref-11","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China","volume":"97","author":"Liu","year":"2019","journal-title":"Bulletin of the World Health Organization"},{"key":"10.7717\/peerj.20275\/ref-12","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/apt.15890","article-title":"Factors associated with the biphasic kinetics of serum HBV RNA in patients with HBeAg-positive chronic hepatitis B treated with nucleos(t)ide analogues","volume":"52","author":"Liu","year":"2020","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"10.7717\/peerj.20275\/ref-13","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"key":"10.7717\/peerj.20275\/ref-14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3760\/cma.j.issn.1007-3418.2017.02.005","article-title":"The potential use of serum HBV RNA to guide the functional cure of chronic hepatitis B","volume":"25","author":"Lu","year":"2017","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"10.7717\/peerj.20275\/ref-15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s11684-017-0590-z","article-title":"Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs","volume":"11","author":"Lu","year":"2017","journal-title":"Frontiers in Medicine"},{"key":"10.7717\/peerj.20275\/ref-16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3748\/wjg.v25.i6.719","article-title":"Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients","volume":"25","author":"Luo","year":"2019","journal-title":"World Journal of Gastroenterology"},{"key":"10.7717\/peerj.20275\/ref-17","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00535-021-01780-5","article-title":"Residual HBV DNA and pgRNA viraemia is associated with hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy","volume":"56","author":"Mak","year":"2021","journal-title":"Journal of Gastroenterology"},{"key":"10.7717\/peerj.20275\/ref-18","doi-asserted-by":"publisher","first-page":"146","DOI":"10.3350\/cmh.2022.0172","article-title":"Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B","volume":"29","author":"Mak","year":"2023","journal-title":"Clinical and Molecular Hepatology"},{"key":"10.7717\/peerj.20275\/ref-19","doi-asserted-by":"publisher","first-page":"17098","DOI":"10.1038\/nmicrobiol.2017.98","article-title":"HBV RNA pre-genome encodes specific motifs that mediate interactions with the viral core protein that promote nucleocapsid assembly","volume":"2","author":"Patel","year":"2017","journal-title":"Nature Microbiology"},{"key":"10.7717\/peerj.20275\/ref-20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.7717\/peerj.20275\/ref-21","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.7717\/peerj.20275\/ref-22","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/hep.27406","article-title":"The global burden of liver disease: the major impact of China","volume":"60","author":"Wang","year":"2014","journal-title":"Hepatology"},{"key":"10.7717\/peerj.20275\/ref-23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"Journal of Hepatology"},{"key":"10.7717\/peerj.20275\/ref-24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijid.2020.07.031","article-title":"Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks","volume":"99","author":"Wang","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"key":"10.7717\/peerj.20275\/ref-25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.08.021","article-title":"Relationship between serum HBV-RNA levels and intrahepatic viral as well as histologic activity markers in entecavir-treated patients","author":"Wang","year":"2017","journal-title":"Journal of Hepatology"}],"container-title":["PeerJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/peerj.com\/articles\/20275.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20275.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20275.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/peerj.com\/articles\/20275.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T08:53:59Z","timestamp":1761814439000},"score":1,"resource":{"primary":{"URL":"https:\/\/peerj.com\/articles\/20275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":25,"alternative-id":["10.7717\/peerj.20275"],"URL":"https:\/\/doi.org\/10.7717\/peerj.20275","archive":["CLOCKSS","LOCKSS","Portico"],"relation":{},"ISSN":["2167-8359"],"issn-type":[{"value":"2167-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"article-number":"e20275"}}